DAVIE, Fla., Nov. 10, 2025 /PRNewswire/ — Regency Square Dental is proud to announce its annual Freedom Day celebration on Saturday, November 15th, honoring local veterans with FREE dental care and a full day of family fun, music, and community…
PLYMOUTH MEETING, Pa., Nov. 10, 2025 /PRNewswire/ — INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it…
Following the group restructuring, Onward Therapeutics, Inc. serves as the global headquarters and holding company in Taiwan.The existing Swiss and French subsidiaries maintain fully operational, focusing on preclinical and clinical development.All licenses, IP rights, and ongoing R&D projects remain unchanged.
LANGHORNE, Pa., Nov. 10, 2025 /PRNewswire/ — TEN Holdings, Inc. (NASDAQ: XHLD) (“TEN Holdings” or the “Company”), through its subsidiary, Ten Events, Inc., a provider of event planning, production, and broadcasting services, today announced its financial results for the quarter…
NEW YORK, Nov. 10, 2025 /PRNewswire/ —
GALWAY, Ireland, Nov. 10, 2025 /PRNewswire/ — The board of directors of TE Connectivity plc (NYSE: TEL), a world leader in connectors and sensors, has appointed Ken Washington to the board, effective November 17, 2025.
Loudoun County authorities are investigating a Monday morning explosion and fire in a dumpster at an Ashburn apartment complex.
ZURICH, Nov. 10, 2025 /PRNewswire/ — Chubb Limited (NYSE: CB) today announced that Susan Spivak has been appointed to Senior Vice President of Investor Relations, effective November 17, 2025.
DUBAI, UAE, Nov. 10, 2025 /PRNewswire/ — Yalla Group Limited (“Yalla” or the “Company”) (NYSE: YALA), the largest Middle East and North Africa (MENA)-based online social networking and gaming company, today announced its unaudited financial results for the third quarter…
STOCKHOLM, Nov. 10, 2025 /PRNewswire/ — Calliditas Therapeutics (Calliditas), an Asahi Kasei company, announced today that primary safety endpoints of a Phase 2a, randomized, double-blind, placebo-controlled trial of setanaxib in patients with Alport syndrome were presented in a High-Impact Clinical…